The new funding is expected to provide a vital capital boost to Africure and supports the company’s plan to strengthen its working capital and increase demand for pharmaceutical goods across over 10 African markets.
“We are delighted to support the company’s growth trajectory as strengthening health systems plays a critical role in Africa’s recovery from the pandemic.
“Our partnership will boost access where there is an urgent need to provide quality and affordable treatment to consumers that need it the most.”
The funding is also expected to help Africure to realise its growth ambitions to develop a range of innovative affordable Africure brands that target chronic disease profiles such as cardiac and diabetes conditions.
“BluePeak’s investment is transformative for our business. This will act as an impetus to our growth trajectory & we are sure this will take us to a critical size,” Sinhue Noronha, Founder and CEO of Africure said.
“We have built a highly competitive pan-African manufacturing capability over the past 5 years.
“This investment will enable us to scale up significantly the number of customers we serve, as well as the number of patients we can reach with affordable, reliable treatments for communicable, infectious, and chronic diseases and conditions.”
Africure was founded in 2017 and the startup claims it has a portfolio of nearly 300 products that spans several therapeutic areas ranging from anti-infectives, analgesics, antiparasitic and respiratory treatments to generic drugs providing critical care for non-communicable diseases, increasingly prevalent in countries across the continent.
BluePeak Private Capital Fund SCSp (the Fund) is an impact-driven private capital fund which reached its first close at US$116.5 million in September 2021.